Mesoblast Ltd ADR [NASDAQ: MESO] closed the trading session at $5.01. The company report on March 25, 2024 at 10:34 PM that United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission
Mesoblast Ltd ADR [NASDAQ: MESO] gained 78.64% or 1.73 points to close at $3.93 with a heavy trading volume of 68338200 shares. The company report on March 25, 2024 at 10:34 PM that United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical
Mesoblast Ltd ADR [NASDAQ: MESO] gained 23.72% or 0.51 points to close at $2.66 with a heavy trading volume of 14719876 shares. The company report on March 10, 2024 at 7:54 PM that United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for
© 2024, Powered by Smart TechOne
